Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

Date publication

août 2019

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MENNECIER Bertrand , Dr SCHOTT Roland , Dr GALLAND Loïck

Tous les auteurs :
Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31491676

Résumé

Brigatinib is a next-generation ALK inhibitor initially developed in ALK-positive NSCLC pretreated with crizotinib.

Mots clés

ALK inhibitor, ALK rearrangement, Advanced non-small cell lung cancer, Brigatinib, Crizotinib, Early access program

Référence

Lung Cancer. 2019 Aug 14;136:109-114